The anti-CD30 antibody conjugate brentuximab vedotin had been reported to be efficacious in two patients with R/R NK/T-cell lymphomas expressing CD30 [99,100], an observation requiring prospective validation. The gene discussed is TNFRSF8; the disease is T-cell non-Hodgkin lymphoma.